Press Releases Choose Year All Items 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 Search Press Releases Found 86 Results August 12, 2024 Surrozen Provides Second Quarter 2024 Financial Results and Business Update June 12, 2024 Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology,to Further Enhance Wnt Signaling June 10, 2024 Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan June 4, 2024 Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis May 9, 2024 Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting May 8, 2024 Surrozen Provides First Quarter 2024 Financial Results and Business Update April 3, 2024 Surrozen Publishes Study in ‘Respiratory Research’ Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis April 1, 2024 Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules April 1, 2024 Surrozen Announces Safety,Pharmacodynamic and Liver Function Data for SZN-043 January 18, 2024 Surrozen Provides Corporate Update on Clinical Programs «12345...»
